What's Going On With TG Therapeutics (TGTX) Stock?

TG Therapeutics, Inc. TGTX shares are moving higher on Friday.

What To Know:

TG Therapeutics launched Briumvi, a drug for the treatment of relapsing forms of MS, in the first quarter of 2023.  The company reported first quarter product revenue from Briumvi alone at $7.8 million and projected continued revenue growth for the drug. 

According to data from Benzinga Pro, TGTX has considerable short interest with 18.59% of available shares currently being sold short.  TGTX stock is also receiving attention from retail investors with the stock currently listed as a top trending ticker on StockTwits and Yahoo!.

Related News: Prestige Wealth Management (PWM) Stock Is Ripping Higher: What's Going On?

TGTX Price Action: According to Benzinga Pro, TG Therapeutics shares are trading 11% higher at $25.58 at the time of publication.

Image: akirEVarga from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!